Press Releases
-
Nov 21, 2019
1st Marketing Application Submission for Gene Therapy Directed at Any Type of HemophiliaBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational...
-
Nov 14, 2019Valoctocogene Roxaparvovec on Track for US and EU Regulatory Submissions by Year End
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare diseases....
-
Nov 14, 2019Company Plans to Provide Topline Phase 3 Data by Year End
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) provided an update on its clinical program for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia, the most...
-
Nov 12, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on...
-
Nov 6, 2019- Key research & development pipeline products and data to be presented, including 54-month Phase 2 vosoritide data update for the treatment of achondroplasia -
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D Day at 8:00am ET on Thursday, November 14, 2019. BioMarin management and external experts will provide an update to the investment...
